Companies · Biotechnology

AltheaDx, Inc.

SAN DIEGO · Biotechnology

Diligence memoA one-page analyst read on AltheaDx, Inc. — recommendation, valuation, rhythm, risks.
$51.8M
Total raised · real
12
Rounds
1.3×
Latest step-up
Top 19%
Sector rank · raised
Series B
Latest stage · inferred · Wed Sep 02 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

AltheaDx, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.22× the median modeled value of Series B Biotechnology companies in 2019–2021 (118 peers) — value vs value, same stage and era.
Dormant
  • Last raise 5.8 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

AltheaDx, Inc. is one of 4291 Biotechnology companies tracked from SAN DIEGO. By capital raised it ranks in the upper tier (ahead of 82% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
28
Investors (latest)
2020-09-02
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeed · 2009-08-13 Raised $3.6M (real) Modeled valuation $159M (est)Seed2009Series A · 2013-05-30 Raised $7.2M (real) Modeled valuation $262M (est)Series A2013Series A · 2014-03-31 Raised $150K (real) Modeled valuation $5.4M (est)Series A2014Series B · 2015-12-11 Raised $20M (real) Modeled valuation $798M (est)Series B2015Series B · 2016-07-01 Raised $2.2M (real) Modeled valuation $88M (est)Series B2016Series B · 2016-09-08 Raised $6.0M (real) Modeled valuation $238M (est)Series B2016Series B · 2017-02-01 Raised $3.0M (real) Modeled valuation $119M (est)Series B2017Series B · 2018-02-23 Raised $831K (real) Modeled valuation $33M (est)Series B2018Series B · 2018-07-27 Raised $2.0M (real) Modeled valuation $78M (est)Series B2018Series B · 2018-12-21 Raised $1.7M (real) Modeled valuation $67M (est)Series B2018Series B · 2019-09-23 Raised $1.3M (real) Modeled valuation $52M (est)Series B2019Seed · 2020-09-02 Raised $2.9M (real) Modeled valuation $115M (est)Seed2020Series B · 2020-09-02 Raised $3.7M (real) Modeled valuation $137M (est)Series B2020Cumulative $55M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$3.6M · 2009
Series A$7.2M · 2013
Series A extension$150K · 2014
Series B$20.1M · 2015
Series B extension$2.2M · 2016
Series B extension$6.0M · 2016
Series B extension$3.0M · 2017
Series B extension$831K · 2018
Series B extension$2.0M · 2018
Series B extension$1.7M · 2018
Series B extension$1.3M · 2019
Bridge · Series B-stage$2.9M · 2020smaller follow-on
Series B extension$3.7M · 2020

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 75%.

Modeled valuation trajectory
$137.3M
Base estimate est.
$7.5M
Conservative case
$511.1M
Upside case
$20.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $158.7M · 2009-08-132009Series A · modeled $262.1M · 2013-05-30Series A · modeled $5.4M · 2014-03-31Series B · modeled $798.1M · 2015-12-11Series B · modeled $88.2M · 2016-07-01Series B · modeled $238.1M · 2016-09-08Series B · modeled $119.1M · 2017-02-01Series B · modeled $33.0M · 2018-02-23Series B · modeled $78.3M · 2018-07-27Series B · modeled $66.7M · 2018-12-21Series B · modeled $52.4M · 2019-09-23Seed · modeled $115.0M · 2020-09-02Series B · modeled $137.3M · 2020-09-022020
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
5.8 yr
Elapsed time used
5.8 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
11 mo
Avg between rounds
$4.7M/yr
Capital velocity
16.9 yr
On record since
2009
First round
13
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 7.2× above median
This company$51.8M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.2× of median
This company$3.7M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 2.1× above median
This company$137.3M
Sector median$64.2M

Raised more than 82% of sector peers (real $). Modeled value above 65% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #105 of 118.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Pandion Therapeutics Holdco LLC · Series B Raised $40.0M · modeled $1.6B (est)Ocular Therapeutix, Inc · Series B Raised $81.0M · modeled $1.5B (est)Insilico Medicine Cayman TopCo · Series B Raised $36.8M · modeled $1.5B (est)Purigen Biosystems, Inc. · Series B Raised $61.9M · modeled $1.4B (est)Lucira Health, Inc. · Series B Raised $32.5M · modeled $1.3B (est)Peptilogics, Inc. · Series B Raised $40.9M · modeled $1.2B (est)Nanotech Energy, Inc. · Series B Raised $31.6M · modeled $1.1B (est)Windtree Therapeutics Inc /De/ · Series B Raised $104.5M · modeled $1.0B (est)Liminal BioSciences Inc. · Series B Raised $67.1M · modeled $1.0B (est)Palladio Biosciences, Inc. · Series B Raised $28.0M · modeled $1.0B (est)Faze Medicines, Inc. · Series B Raised $30.4M · modeled $998.4M (est)Inivata Ltd · Series B Raised $25.0M · modeled $992.2M (est)AltheaDx, Inc. (this company) Raised $51.8M · modeled $137.3M (est)AltheaDx, Inc.
CompanyStageRaised · realValue · estvs peer med.
Pandion Therapeutics Holdco LLCSeries B$40.0M$1.6B2.58×
Ocular Therapeutix, IncSeries B$81.0M$1.5B2.42×
Insilico Medicine Cayman TopCoSeries B$36.8M$1.5B2.37×
Purigen Biosystems, Inc.Series B$61.9M$1.4B2.22×
Lucira Health, Inc.Series B$32.5M$1.3B2.10×
Peptilogics, Inc.Series B$40.9M$1.2B1.90×
Nanotech Energy, Inc.Series B$31.6M$1.1B1.82×
Windtree Therapeutics Inc /De/Series B$104.5M$1.0B1.71×
Liminal BioSciences Inc.Series B$67.1M$1.0B1.67×
Palladio Biosciences, Inc.Series B$28.0M$1.0B1.63×
Faze Medicines, Inc.Series B$30.4M$998.4M1.62×
Inivata LtdSeries B$25.0M$992.2M1.61×
AltheaDx, Inc. this companySeries B$51.8M$137.3M0.22×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$3.6M2009-08-13$17.9M$158.7M85%
Series A$7.2M2013-05-30$33.0M$262.1M85%
Series A$150K2014-03-31$682K$5.4M85%
Series B$20.1M2015-12-11$111.7M$798.1M85%
Series B$2.2M2016-07-01$12.3M$88.2M85%
Series B$6.0M2016-09-08$33.3M$238.1M85%
Series B$3.0M2017-02-01$16.7M$119.1M90%
Series B$831K2018-02-23$4.6M$33.0M90%
Series B$2.0M2018-07-27$11.0M$78.3M90%
Series B$1.7M2018-12-21$9.3M$66.7M90%
Series B$1.3M2019-09-23$7.3M$52.4M90%
Seed$2.9M2020-09-02$14.3M$115.0M90%
Series B$3.7M2020-09-02$20.7M$137.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$3.6M2009-08-13
    • First recorded raise — entered as Seed.
    • 4 investors on this round.
  2. Series A$7.2M2013-05-30
    • Raised again after 46 mo — slower than the ~14 mo sector norm.
    • Round 2.0× larger than the prior — scaling up.
    • 12 investors on this round.
  3. Series A$150K2014-03-31
    • Raised 10 mo later, in step with the ~14 mo sector norm.
    • Round 48.3× smaller than the prior — bridge or down round.
    • Switched to Rule 506(b) (was Rule 06).
    • 2 investors on this round.
  4. Series B$20.1M2015-12-11
    • Raised 20 mo later, in step with the ~14 mo sector norm.
    • Round 134.0× larger than the prior — scaling up.
    • 28 investors on this round.
  5. Series B$2.2M2016-07-01
    • Came back fast: 7 mo vs the ~14 mo sector norm.
    • Round 9.1× smaller than the prior — bridge or down round.
    • 5 investors on this round.
  6. Series B$6.0M2016-09-08
    • Came back fast: 2 mo vs the ~14 mo sector norm.
    • Round 2.7× larger than the prior — scaling up.
    • 1 investor on this round.
  7. Series B$3.0M2017-02-01
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 2.0× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  8. Series B$831K2018-02-23
    • Raised 13 mo later, in step with the ~14 mo sector norm.
    • Round 3.6× smaller than the prior — bridge or down round.
    • 5 investors on this round.
  9. Series B$2.0M2018-07-27
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 2.4× larger than the prior — scaling up.
    • 6 investors on this round.
  10. Series B$1.7M2018-12-21
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 5 investors on this round.
  11. Series B$1.3M2019-09-23
    • Raised 9 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 5 investors on this round.
  12. Seed$2.9M2020-09-02
    • Raised 11 mo later, in step with the ~14 mo sector norm.
    • Round 2.2× larger than the prior — scaling up.
    • 5 investors on this round.
  13. Series B$3.7M2020-09-02
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.3× larger than the prior — scaling up.
    • 28 investors on this round.
Intelligence
2021 ~Q3
Modeled next raise · ~11mo cadence
$4.9M
Modeled next size est.range $3.7M$7.8M
1.3×
Last step-up
$4.7M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Wei Li6 other2015-12
Magda Marquet5 other2009-08
Andrew Jackson3 other2017-02
David Nikodem3 other2015-12
Jason Liu3 other2015-12
J. Matthew Mackowski3 other2009-08
John Wu3 other2017-02
Jeffrey G. Black2 other2014-03
Deval A Lashkari1 other2009-08
Francois Ferre1 other2009-08
James B Glavin1 other2009-08
Yuh-geng Tsay1 other2015-12
Ann A Kessler2013-05
Ann Kessler2015-12
Ann Matthew Kessler2014-03
Carin A Sandvik2013-05
Carin Sandvik2014-03
Deval Matthew Lashkari2014-03
Feng Cao2018-07
Francois G. Ferre2014-03
Greg A Hamilton2013-05
Greg Hamilton2014-03
James G. Glavin2014-03
Jorge Garces2015-12
Registry & provenance

AltheaDx, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1470592
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Ivenix, Inc.BiotechnologySeries B$82.9M$396.9Mnetwork2 shared operators · same sector · same stage
Biomatrica, Inc.BiotechnologySeries B$22.7M$720.2Mnetwork1 shared operator · same sector · same stage
Eterna Therapeutics Inc.BiotechnologySeries A$53.1M$26.5Mnetwork1 shared operator · same sector
Spear Bio Inc.BiotechnologySeries C$50.1M$391.9Mnetwork1 shared operator · same sector
Visiongate IncBiotechnologySeries B$51.8M$148.8Msame sector · same stage
Capricor Therapeutics, Inc.BiotechnologySeries B$51.9M$147.2Msame sector · same stage
Lucid Diagnostics Inc.BiotechnologySeries B$51.7M$132.1Msame sector · same stage
Synnovation Therapeutics, Inc.BiotechnologySeries B$52.0M$136.2Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Altis Biosystems, Inc.BiotechnologySeed$6.8M88%
AltPep CorpBiotechnologySeries C$837.9M85%
Trailhead Biosystems Inc.BiotechnologySeries B$75.7M85%
Myotherix, Inc.BiotechnologySeries A$286.7M83%
Ambergen, Inc.BiotechnologySeries A$77.1M83%
Otologic Technologies, Inc.BiotechnologyPre-Seed$1.1M83%
Steep Hill, Inc.BiotechnologySeries A$144.6M83%
Mitotherapeutix, LLCBiotechnologySeed$131.8M83%
Frequently asked
How much funding has AltheaDx, Inc. raised?
AltheaDx, Inc. has raised approximately $51.8M in disclosed capital across 12 recorded financing rounds, aggregated from public filings.
What is AltheaDx, Inc.'s estimated valuation?
Provath's modeled valuation for AltheaDx, Inc. is approximately $137.3M (modeled range $7.5M–$511.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is AltheaDx, Inc. at?
AltheaDx, Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Wed Sep 02.
What does AltheaDx, Inc. do and where is it based?
AltheaDx, Inc. operates in the Biotechnology sector, based in SAN DIEGO.
Explore related

See where AltheaDx, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at AltheaDx, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.